NCT05546385终止不适用
A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled, Parallel-group, Group-sequential Study to Investigate Safety and Effectiveness of the Rehaler Partial Rebreathing Device, in Adults Suffering From Migraine With Aura
Rehaler30 个研究点 分布在 2 个国家目标入组 142 人开始时间: 2023年8月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 142
- 试验地点
- 30
- 主要终点
- Absence of Moderate or Severe Pain at 2 Hours (AMSP2)
研究概览
简要总结
A prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study to investigate safety and effectiveness of the Rehaler partial rebreathing device, in adults suffering from migraine with aura
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Sham device
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant has migraine with typical aura (ICHD3 classification 1.2.1) with the additional criterion that historically in more than 75% of cases of aura a moderate or severe headache begins between 10 and 60 minutes after aura onset.
- •Participant has had 3 or more migraine-with-aura attacks over the last six months.
- •Participant is 18 to 65 years of age.
- •Participant's age at onset of migraine with aura was less than 50 years.
- •If participant is taking migraine prophylactic drugs, the dose must have been stable for three months or more.
- •Participant agrees to withhold usual acute migraine medications until at least two hours after treatment with the study device.
- •Participant does not plan to initiate new (and/or change existing) migraine prophylaxis medication for the duration of Stage 1 of the study.
- •For female participants: is willing to use adequate contraception during study participation
- •Participant owns a smartphone compatible with the ePRO study diary app.
- •Participant agrees to use the study device as intended, comply with all study requirements including treatment, follow-up visits, and recording required study data in the ePRO app.
- •Participant is willing and able to provide written informed consent.
排除标准
- •Participant has a history of chronic pulmonary disease (e.g. Chronic Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis).
- •Participant has a history of severe cardiovascular disease (e.g. symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure) or cerebrovascular disease (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery).
- •Participant has a history of intracranial hyper/hypo-tension.
- •Participant has a history of cerebral aneurysm.
- •Participant has had previous brain surgery, including stenting.
- •Anaemia, defined as a hemoglobin concentration in capillary blood lower than 11g/dL
- •Participant has a baseline SPO2 level which is lower than 95% performed at Site Visit
- •Participant has 15 or more headache days per month
- •Participant has medication-overuse headache (ICHD3 classification 8.2).
- •Participant has a known history or suspicion of recurring secondary headache which in the opinion of the investigator may interfere with the study.
- •Hemiplegic migraine
- •Participant has other significant and relevant pain problem (e.g. cancer pain, fibromyalgia or other head or facial pain disorders)
- •Participant has a known history or suspicion of substance abuse or addiction (within the last 5 years) that in the opinion of the investigator may confound the study assessments.
- •Participant has a history of psychiatric or cognitive disorder and/or behavioural problems which in the opinion of the investigator may interfere with the study.
- •Participant belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self-assessments is compromised (e.g. homeless, developmentally disabled, prisoner).
- •For female participants: is pregnant or actively trying to become pregnant.
- •Participant is participating in any other clinical investigation or has participated in an interventional clinical trial in the preceding 30 days.
- •Participant has any condition that according to the investigator may pose the participant at risk or provide confounding data.
- •Participant is unable, as perceived by study personnel, to correctly understand and follow the instructions for use of the device and ePRO app.
- •Sickle Cell Disease
- •Participant is being treated with nerve blocks or injections for migraine prophylaxis on a regularly scheduled basis (including Botox, Aimovig/Erenumab, Ajovy/Fremanezumab, Emgality/Galcanezumab or Vyepti/Eptinezumab).
结局指标
主要结局
Absence of Moderate or Severe Pain at 2 Hours (AMSP2)
时间窗: 2 hours
The percentage of attacks in which the participant reported absence of headache of moderate or severe intensity at 2 hours post-treatment initiation
次要结局
- Pain Freedom at 2 Hours (PF2)(2 hours)
- Freedom From Most Bothersome Symptom at 2 Hours (MBSF2)(2 hours)
- Sustained Pain Freedom at 24 Hours (SPF24)(24 hours)
- Headache Score at 2 Hours (HS2)(2 hours)
- Most Bothersome Symptom Score at 2 Hours (MBS2).(2 hours)
- Functional Disability Score at 2 Hours (FDS2)(2 hours)
- Light Sensitivity Score at 2 Hours (LSS2)(2 hours)
- Attacks With Use of Rescue Medication From the 2 Hours' Time Point Until 24 Hours (Res24)(24 hours)
- Participant Satisfaction at 48 Hours (PS48)(48 hours)
- Nausea Score at 2 Hours (NS2)(2 hours)
- Sound Sensitivity Score at 2 Hours (SSS2)(2 hours)
- Freedom From Relapse at 48 Hours (FR48)(48 hours)
研究者
研究点 (30)
Loading locations...
相似试验
Unknown
不适用
The Effect of a New Infant Formula on Growth and Cognition in Healthy Term InfantsChild DevelopmentNCT04508257Heilongjiang Feihe Dairy Co. Ltd.450
Unknown
不适用
Safety and Nutritional Adequacy of a New Infant Formula in Healthy Term InfantsChild DevelopmentNCT04013087Heilongjiang Feihe Dairy Co. Ltd.450
已完成
不适用
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or AnxietyDepressionAnxietyNCT02878928AltheaDx579
终止
3 期
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative ProctitisProctitis, UlcerativeNCT01016262Forest Laboratories119
已完成
3 期
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke TherapyIschemic StrokeNCT02793687Pharmasoft150